Penn I3 Presentations at DDW 2024 Convention

Picture
Mo1830 examining the need for washout periods when switching a patients biologic therapy.
The work showed that we do not need full biologic washouts to decrease infection risk when moving to new therapies in IBD treatments.
Picture
  • Poster on impact of GLP1 agonist on inflammatory biomarkers in patients with IBD. Statistically significant decrease in CRP from baseline to 3 months on GLP1 therapy.
Collaboration spearheaded by @KHamiltonPhD with help from http://wwwi3study.org that determined epithelial pathogenesis in CD allowing greater disease understanding & potential new therapeutic targets
Picture
Tu1843 & Tu1844 multi-center PREVENT COVID work showing: patients with IBD  have sustained effectiveness of the COVID19 vaccination and vaccine titers don't correlate with COVID19 risk in IBD
MILESTONE-IBD is a national year-long educational program for Advanced IBD fellows across the country. They had their graduation reception at DDW! Congrats on their Graduation. They are the future of IBD care!